Photocure's Cevira Gains China Approval, Expanding Non-Invasive Cervical Therapy Market

Event summary

  • Asieris Pharmaceuticals received China's NMPA approval for Cevira (APL-1702), a non-invasive therapy for cervical precancerous lesions, enabling commercial launch in China.
  • Photocure, which licensed Cevira to Asieris, is eligible for a milestone payment with further sales milestones based on future revenue.
  • Cevira is the first non-surgical, non-invasive therapy approved for cervical intraepithelial neoplasia grade 2 (CIN2) in China.
  • The European Medicines Agency (EMA) accepted the marketing authorization application (MAA) for Cevira in February 2026, with a separate Phase III trial planned for U.S. approval.

The big picture

Cevira's approval in China marks a significant step in addressing an unmet medical need for non-invasive cervical lesion treatment. The therapy's potential to reshape the treatment landscape could drive market expansion, particularly in regions with high prevalence of cervical precancerous lesions. Photocure's strategic partnership with Asieris positions it to benefit from milestone payments and future revenue streams, while the ongoing regulatory processes in Europe and the U.S. will be critical for broader market access.

What we're watching

Market Penetration
The pace at which Cevira can capture market share in China, where the cervical precancerous lesions treatment landscape has been dominated by invasive procedures.
Regulatory Progress
Whether Cevira can secure approvals in the European and U.S. markets, given the EMA's acceptance of the MAA and the FDA's agreement on a Phase III trial design.
Revenue Impact
How the milestone payments and future sales milestones from Cevira's commercialization in China will affect Photocure's financial performance.